Carryover effect analysis
Treatment . | 35 IU/kg . | 25 IU/kg . |
|---|---|---|
| Segment 1, rFVIII | ||
| Mean bleeding-free time,* d (median) | 7.2 (7.0) | 5.7 (6.0) |
| SD, d | 2.2 | 2.6 |
| No. of patients | 11 | 12 |
| Segment 2, PEGLip rFVIII, infusion 1 | ||
| Mean bleeding-free time,* d (median) | 8.7 (7.0) | 6.0 (5.0) |
| SD, d | 5.8 | 4.0 |
| No. of patients | 11 | 12 |
| Segment 3, PEGLip rFVIII, infusion 2 | ||
| Mean bleeding-free time,* d (median) | 10 (7.0) | 7.7 (9.0) |
| SD | 7.6 | 2.7 |
| No. of patients | 11 | 9 |
Treatment . | 35 IU/kg . | 25 IU/kg . |
|---|---|---|
| Segment 1, rFVIII | ||
| Mean bleeding-free time,* d (median) | 7.2 (7.0) | 5.7 (6.0) |
| SD, d | 2.2 | 2.6 |
| No. of patients | 11 | 12 |
| Segment 2, PEGLip rFVIII, infusion 1 | ||
| Mean bleeding-free time,* d (median) | 8.7 (7.0) | 6.0 (5.0) |
| SD, d | 5.8 | 4.0 |
| No. of patients | 11 | 12 |
| Segment 3, PEGLip rFVIII, infusion 2 | ||
| Mean bleeding-free time,* d (median) | 10 (7.0) | 7.7 (9.0) |
| SD | 7.6 | 2.7 |
| No. of patients | 11 | 9 |
Bleeding-free days following first on-demand treatment for each dosing cohort.